Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Rocket Pharmaceuticals (RCKT) shares soar on alignment with FDA on trial; Stifel positive
September 13, 2023 6:50 AM EDTRocket Pharmaceuticals (NASDAQ: RCKT) stock rose 15.5% in premarket trading on Wednesday after the gene therapy developer that it has reached an agreement with the U.S. Food and Drug Administration (FDA) regarding the global Phase 2 trial of RP-A501.
The trial aims to address Danon... More
